Do we know the Zenith business model around ZEN-3694 ??,,,are we selling indications only?,,,,,marketing for royalties only?,,,both,,giving it away,,,,other?,,,what dollar numbers are we talking?,,,any insight here?

As an example; "Under the terms of the agreement, Newsoara will have the rights to develop, market, and distribute ZEN-3694 for all indications in China, Hong Kong, Taiwan, and Macau (the “Territories). Newsoara will pay Zenith Epigenetics upfront and near-term development milestone payments totaling US$15 million."

Knowing what we do know, and that is, our team is out of their league dealing with big pharma and undoubtedly have no business prowess, we must ask, how many ways can we fail to accomplish achieving a win win in any deal?